Literature DB >> 27623944

IL-13 receptor α2 stimulates human glioma cell growth and metastasis through the Src/PI3K/Akt/mTOR signaling pathway.

Ming Tu1, Wei Wange2, Lin Cai1, Penglei Zhu1, Zhichao Gao1, Weiming Zheng3.   

Abstract

Glioma is a malignant tumor that affects all kinds of people all over the world. It demonstrates remarkable infiltrative and invasive features. The high expression of interleukin-13 receptor subunit alpha-2 (IL-13Rα2) reportedly plays a pivotal role in some cancers. However, whether IL-13Rα2 contributes to glioma remains unknown. This study demonstrates that IL-13Rα2 is significantly up-regulated in human glioma tissue samples. It is also associated with late stages of disease progression and diminished survival in glioma patients. Gain- and loss-of-function studies demonstrate that IL-13Rα2 promotes the growth, migration, and invasion of glioma cells. In addition, mechanistic investigations show that IL-13Rα2 activates Scr, phosphatidylinositol 3 kinase (PI3K), Akt, and mTOR. Also, restraining Scr in glioma cells attenuates the activation of Scr/PI3K/Akt/mTOR pathway by IL-13Rα2, whereas the silencing of Scr markedly rescues the pro-invasive effect of IL-13Rα2. In conclusion, our results suggest that the high expression of IL-13Rα2 is significantly associated with the growth and metastasis of human glioma cells via the Scr/PI3K/Akt/mTOR pathway, while IL-13Rα2 may be a potential therapeutic target for glioma treatment.

Entities:  

Keywords:  Glioma; IL-13Rα2; Invasion; Scr

Mesh:

Substances:

Year:  2016        PMID: 27623944     DOI: 10.1007/s13277-016-5346-x

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  36 in total

1.  Src family kinases differentially influence glioma growth and motility.

Authors:  Laura J Lewis-Tuffin; Ryan Feathers; Priya Hari; Nisha Durand; Zhimin Li; Fausto J Rodriguez; Katie Bakken; Brett Carlson; Mark Schroeder; Jann N Sarkaria; Panos Z Anastasiadis
Journal:  Mol Oncol       Date:  2015-06-10       Impact factor: 6.603

2.  Human cathelicidin LL-37 inhibits platelet aggregation and thrombosis via Src/PI3K/Akt signaling.

Authors:  Wen Su; Yahui Chen; Caihui Wang; Xue Ding; Gamariel Rwibasira; Yi Kong
Journal:  Biochem Biophys Res Commun       Date:  2016-03-21       Impact factor: 3.575

3.  High expression of IL-13 receptor α2 in colorectal cancer is associated with invasion, liver metastasis, and poor prognosis.

Authors:  Rodrigo Barderas; Rubén A Bartolomé; María Jesús Fernandez-Aceñero; Sofia Torres; J Ignacio Casal
Journal:  Cancer Res       Date:  2012-04-13       Impact factor: 12.701

4.  Genetic Inactivation of ATRX Leads to a Decrease in the Amount of Telomeric Cohesin and Level of Telomere Transcription in Human Glioma Cells.

Authors:  Rita Eid; Marie-Véronique Demattei; Harikleia Episkopou; Corinne Augé-Gouillou; Anabelle Decottignies; Nathalie Grandin; Michel Charbonneau
Journal:  Mol Cell Biol       Date:  2015-06-08       Impact factor: 4.272

5.  Survival and low-grade glioma: the emergence of genetic information.

Authors:  Elizabeth B Claus; Kyle M Walsh; John K Wiencke; Annette M Molinaro; Joseph L Wiemels; Joellen M Schildkraut; Melissa L Bondy; Mitchel Berger; Robert Jenkins; Margaret Wrensch
Journal:  Neurosurg Focus       Date:  2015-01       Impact factor: 4.047

6.  Killing effect of interleukin-13 receptor alpha 2 (IL-13Ralpha2) sensitized DC-CTL cells on human glioblastoma U251 cells.

Authors:  Xinjiang Yan; Zhipeng Su; Jing Zhang; Zhebao Wu; Sheng Ye; Xianghe Lu; Jinsen Wu; Yanjun Zeng; Weiming Zheng
Journal:  Cell Immunol       Date:  2010-03-27       Impact factor: 4.868

Review 7.  IL-13 receptor-directed cancer vaccines and immunotherapy.

Authors:  Hideyuki Nakashima; Syed R Husain; Raj K Puri
Journal:  Immunotherapy       Date:  2012-04       Impact factor: 4.196

8.  IL-13Rα2 mediates PNR-induced migration and metastasis in ERα-negative breast cancer.

Authors:  Z Zhao; L Wang; W Xu
Journal:  Oncogene       Date:  2014-04-21       Impact factor: 9.867

9.  IL-13 receptor α2 is a negative prognostic factor in human lung cancer and stimulates lung cancer growth in mice.

Authors:  Mian Xie; Xiao-jun Wu; Jin-jun Zhang; Chao-sheng He
Journal:  Oncotarget       Date:  2015-10-20

10.  Phase I trial of systemic intravenous infusion of interleukin-13-Pseudomonas exotoxin in patients with metastatic adrenocortical carcinoma.

Authors:  Yi Liu-Chittenden; Meenu Jain; Parag Kumar; Dhaval Patel; Rachel Aufforth; Vladimir Neychev; Samira Sadowski; Sudheer K Gara; Bharat H Joshi; Candice Cottle-Delisle; Roxanne Merkel; Lily Yang; Markku Miettinen; Raj K Puri; Electron Kebebew
Journal:  Cancer Med       Date:  2015-03-13       Impact factor: 4.711

View more
  16 in total

Review 1.  CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges.

Authors:  Stephen J Bagley; Arati S Desai; Gerald P Linette; Carl H June; Donald M O'Rourke
Journal:  Neuro Oncol       Date:  2018-10-09       Impact factor: 12.300

2.  99mTc-labeled peptide targeting interleukin 13 receptor α 2 for tumor imaging in a cervical cancer mouse model.

Authors:  Yujing Du; Zhao Chen; Xiaojiang Duan; Ping Yan; Chunli Zhang; Lei Kang; Rongfu Wang
Journal:  Ann Nucl Med       Date:  2022-01-15       Impact factor: 2.668

Review 3.  Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma.

Authors:  Lisa Feldman; Christine Brown; Behnam Badie
Journal:  Neuromolecular Med       Date:  2021-10-19       Impact factor: 4.103

Review 4.  Precision Neuro-oncology: the Role of Genomic Testing in the Management of Adult and Pediatric Gliomas.

Authors:  Lori A Ramkissoon; Nicholas Britt; Alexander Guevara; Emily Whitt; Eric Severson; Pratheesh Sathyan; Laurie Gay; Julia Elvin; Jeffrey S Ross; Charlotte Brown; Kimberly Stogner-Underwood; Ryan Mott; David Kram; Roy Strowd; Glenn J Lesser; Shakti H Ramkissoon
Journal:  Curr Treat Options Oncol       Date:  2018-06-21

Review 5.  Chimeric Antigen Receptor T-Cell Therapy: Updates in Glioblastoma Treatment.

Authors:  Lisa Feldman; Christine Brown; Behnam Badie
Journal:  Neurosurgery       Date:  2021-05-13       Impact factor: 4.654

6.  Design considerations of an IL13Rα2 antibody-drug conjugate for diffuse intrinsic pontine glioma.

Authors:  Xiaolei Lian; Dina Kats; Samuel Rasmussen; Leah R Martin; Anju Karki; Charles Keller; Noah E Berlow
Journal:  Acta Neuropathol Commun       Date:  2021-05-17       Impact factor: 7.801

7.  IL13Rα2 siRNA inhibited cell proliferation, induced cell apoptosis, and suppressed cell invasion in papillary thyroid carcinoma cells.

Authors:  Mingjun Gu
Journal:  Onco Targets Ther       Date:  2018-03-09       Impact factor: 4.147

8.  miR‑29a suppresses IL‑13‑induced cell invasion by inhibiting YY1 in the AKT pathway in lung adenocarcinoma A549 cells.

Authors:  Yu Zhang; Shujin He; Renmei Mei; Yurong Kang; Jing Duan; Ran Wei; Chuqi Xiang; Yemeng Wu; Xiangtong Lu; Zhenyu Cai; Lixia Xiong
Journal:  Oncol Rep       Date:  2018-04-04       Impact factor: 3.906

9.  The Gαh/phospholipase C-δ1 interaction promotes autophagosome degradation by activating the Akt/mTORC1 pathway in metastatic triple-negative breast cancer.

Authors:  Hui-Yu Lin; Chia-Hao Kuei; Hsun-Hua Lee; Che-Hsuan Lin; Jing-Quan Zheng; Hui-Wen Chiu; Chi-Long Chen; Yuan-Feng Lin
Journal:  Aging (Albany NY)       Date:  2020-07-01       Impact factor: 5.682

10.  IL13RA2 targeted alpha particle therapy against glioblastomas.

Authors:  Anirudh Sattiraju; Kiran Kumar Solingapuram Sai; Ang Xuan; Darpan N Pandya; Frankis G Almaguel; Thaddeus J Wadas; Denise M Herpai; Waldemar Debinski; Akiva Mintz
Journal:  Oncotarget       Date:  2017-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.